Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability and efficacy of
natalizumab in subjects diagnosed with moderate to severe rheumatoid arthritis (RA) receiving
concomitant treatment with methotrexate (MTX). It is thought that natalizumab may stop the
movement of certain white blood cells, known as lymphocytes, into joint tissue. These cells
are thought to cause damage in the joints leading to the symptoms of RA.